Nurkalem Zekeriya, Yildirimtürk Özlem, Özcan Kazim Serhan, Kul Şeref, Çanga Yiğit, Satılmış Seçkin, Bozbeyoğlu Emrah, Kaya Cevdet
Bezmialem Vakif University, Faculty of Medicine, Cardiology Department, Istanbul/Turkey.
Kardiol Pol. 2014;72(3):275-9. doi: 10.5603/KP.a2013.0287. Epub 2013 Oct 21.
The aim of this study was to evaluate the effect of atorvastatin and rosuvastatin on erectile dysfunction in hypercholesterolaemic patients.
Ninety consecutive male hypercholesterolaemic patients (mean age 50.4 ± 7.9 years) who were otherwise healthy were included into the study prospectively. None of the patients had any cardiovascular risk factors except hypercholesterolaemia.The patients were divided into two groups. One group received atorvastatin while the other group was given rosuvastatin. All patients were followed for six months and International Index of Erectile Function-5 (IIEF-5) score and blood samples were re-evaluated.
Patients were in similar ages in both groups. There were also no statistical differences in terms of blood glucose levels, total cholesterol, low density lipoprotein, high density lipoprotein, triglyceride and mean IIEF score in both groups at the beginning. After six months, no IIEF score changes were observed in the rosuvastatin group after the medication. However, the IIEF score was significantly lower in the atorvastatin group (p = 0.019).
Rosuvastatin showed no effect on erectile dysfunction, while we observed increased erectile dysfunction with atorvastatin. Our study reveals that different statin types may have different effects on erectile dysfunction.
本研究旨在评估阿托伐他汀和瑞舒伐他汀对高胆固醇血症患者勃起功能障碍的影响。
前瞻性纳入90例连续的男性高胆固醇血症患者(平均年龄50.4±7.9岁),这些患者无其他健康问题。除高胆固醇血症外,所有患者均无任何心血管危险因素。患者被分为两组。一组接受阿托伐他汀治疗,另一组给予瑞舒伐他汀。所有患者随访6个月,重新评估国际勃起功能指数-5(IIEF-5)评分和血样。
两组患者年龄相似。两组在开始时的血糖水平、总胆固醇、低密度脂蛋白、高密度脂蛋白、甘油三酯和平均IIEF评分方面也无统计学差异。6个月后,瑞舒伐他汀组用药后IIEF评分无变化。然而,阿托伐他汀组的IIEF评分显著降低(p = 0.019)。
瑞舒伐他汀对勃起功能障碍无影响,而我们观察到阿托伐他汀会增加勃起功能障碍。我们的研究表明,不同类型的他汀类药物对勃起功能障碍可能有不同影响。